Incidence, clinical outcomes, and therapeutic approaches of capsule endoscopy-related adverse events in a large study population

Data de publicació: 01/12/2015

Autors de IIS La Fe

Vicente Pons Beltrán

Autor

Autors aliens a IIS La Fe

Fernandez-Urien, I
Carretero, C
Gonzalez, B
Caunedo, A
Valle, J
Redondo-Cerezo, E
Lopez-Higueras, A
Valdes, M
Menchen, P
Fernandez, P
Munoz-Navas, M
Jimenez, J
Herrerias, JM

Grups d'Investigació

Endoscopia Digestiva y Hepática

Leader

Vicente Pons Beltrán

Abstract

Introduction: Capsule endoscopy (CE) has become a first-line tool for small bowel (SB) examination. However, adverse events (AEs), such as CE retention or aspiration, may occur. The aims of this study were to evaluate incidence, clinical outcomes and therapeutic approaches of CE-related AEs in the largest series published to date. Methods: Data from 5428 procedures performed at 12 institutions between August 2001 and January 2012 were retrospectively analyzed. Baseline patient characteristics; procedure; type, localization and symptoms before/after AEs; previous patency tests performed; therapeutic management and patient's outcome were recorded. Results: The overall incidence of CE-related AEs was 1.9%: 2.0% for SB, 0.9% for esophageal and 0.5% for colon CE. The incidence of capsule retention was significantly higher than capsule aspiration (1.87% vs. 0.003%; p < 0.05), in patients suffering from inflammatory bowel disease (IBD) than in obscure GI bleeding (OGIB) (3.3% vs. 1.5%; p < 0.05) and in patients with the combination of nausea/vomiting, abdominal pain and distension. The SB was the most frequent localization of retention (88.2%). The use of patency tests -except for Patency capsule-before CE was not a good predictor for AEs. Most of the patients with AEs developed no or mild symptoms (97%) and were managed by non-surgical methods (64.4%). Conclusions: CE-related AEs are uncommon and difficult to predict by imagiological examinations. SB retention, that is usually asymptomatic, is the most frequent AE. In absence of symptoms, non-surgical management of CE-related AEs is recommended.

Dades de la publicació

ISSN/ISSNe:: 1130-0108, 2340-4167
Tipus:: Article
Pàgines:: 745-752
DOI:
PubMed:: 26671587
Factor d'Impacte:: 0,377 SCImago ℠
Quartil:: Q3 SCImago ℠

Documents

No hi ha documents

Mètriques

Filiacions

Keywords

Capsule endoscopy; Adverse events; Small bowel; Retention; Aspiration

Campos d'Estudi

Projectes associats

RED DE INNOVACION EN TECNOLOGIAS MEDICAS Y SANITARIAS - RED ITEMAS

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

RD09/0077/00156 . INSTITUTO DE SALUD CARLOS III . 2010

ESTUDIO DE FASE III, ALEATORIZADO, A DOBLE CIEGO, CONTROLADO CON PLACEBO SOBRE TERAPIA ADYUVANTE CON VEMURAFENIB (RO5185426) EN PACIENTES CON MELANOMA CUTÁNEO CON MUTACIÓN DE BRAF RESECADO QUIRÚRGICAMENTE CON ALTO RIESGO DE RECIDIVA.

Investigador Principal: ROBERTO PEDRO DÍAZ BEVERIDGE

GO27826 . 2013

ESTUDIO ALEATORIZADO Y ABIERTO, PARA COMPARAR DURANTE 26 SEMANAS EL EFECTO DEL TRATAMIENTO CON GEL INTESTINAL DE LEVODOPA-CARBIDOPA (GILC) Y DEL TRATAMIENTO MÉDICO ÓPTIMO (TMO) SOBRE LOS SÍNTOMAS NO MOTORES (SNM) EN PACIENTES CON ENFERMEDAD DE PARKINSON AVANZADA - ESTUDIO INSIGHTS.

Investigador Principal: IRENE MARTÍNEZ TORRES

M12-927 . 2015

IMPACTO DE LA PAPILOTOMIA DURANTE LA COLANGIOPANCREATOGRAFÍA RETRÓGRADA ENDOSCÓPICA (CPRE) PARA LA IMPLANTACION DE UN STENT BILIAR METALICO NO CUBIERTOEN PACIENTES CON ICTERICIA OBSTRUCTIVA POR TUMORES MALIGNOS DE PANCREAS

Investigador Principal: VICENTE PONS BELTRÁN

PAP-ADE-01

ESTUDIO ALEATORIZADO, ENMASCARADO, CONTROLADO CON PLACEBO SOBRE LOS EFECTOS DE ADALIMUMAB INTRALESIONAL EN ESTENOSIS INTESTINALES DE PACIENTES CON ENFERMEDAD DE CROHN.

Investigador Principal: LIDIA ARGÜELLO VIUDEZ

CSAI